· Clinical research
Phase 3 lymphoma trial of JS203 and chemotherapy doses first patient
Junshi reported first patient dosing in a Phase 3 study of JS203 plus chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
The study compares the investigational regimen with rituximab plus chemotherapy. The trial is registered as NCT07808827.
Read the full company release